The Future of Affordable Drugs

Imprimis Pharmaceuticals is striving to provide affordable, safe generic drugs in the US, starting with a cheaper alternative to Daraprim for treating infections in HIV-positive individuals. The manufacturing rights to Daraprim were purchased by Turing Pharmaceuticals in September, with prices rising from $13 to $750 overnight, provoking outrage from politicians and HIV/AIDS charities alike. Continue reading “The Future of Affordable Drugs”